US Pharma MarketingEli Lilly has splashed up to $3.8 billion on an infectious disease pipeline, acquiring Curevo, LimmaTech Biologics and Vaccine Company to extend its shopping spree into viral and bacterial pathogen R&D.
Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues
Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Source: FierceBiotech